Sovleplenib

DB17557InvestigationalSmall molecule

Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine...

Mechanism: Pharmacologically active on Tyrosine-protein kinase SYK
Curator reviewed
Formula / weight: C₂₄H₃₀N₆O₃S · 482.6 g/mol (avg)

Resolves to

Compound

UNII9CL6353KHOCAS1415792-84-5

Structure

InChIKeyNJIAKNWTIVDSDA-FQEVSTJZSA-NSMILESCS(=O)(=O)N1CCC(CC1)C1=CC=C(C=C1)C1=CC2=NC=CN=C2C(NC[C@@H]2CNCCO2)=N1

Targets

P43405SYK

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sovleplenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account